Sodium Pyruvate

Journal of Medicinal Chemistry Publishes Study Demonstrating BTS's Advantages in Cancer Care IRVINE, Calif., Nov. 21, 2023 /PRNewswire/ -- TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, today announced groundbreaking findings from its recent research, heralding a new chapter in company's pursuit of making Boron Neutron Capture Therapy (BNCT) a viable and globally accepted cancer treatment. The study focused on the development and boron delivery capabilities of Boronotyrosine (BTS), a novel borylated amino acid analogue that will redefine the cancer-fighting potential of BNCT. Published in the Journal of Medicinal Chemistry, this study highlights BTS's potential to improve BNCT, a cutting-edge cancer therapy modality that combines boronated drugs and a particle accelerator-based neutron source to precisely target and kill cancer cells with minimal damage to healthy tissue. This study demonstrates BTS's unparalleled efficiency in delivering boron—a critical element in BNCT—to LAT1-expressing cancer cells, outperforming the only approved drug for BNCT, Boronophenylalanine (BPA), in both in vivo and in vitro models. The findings reveal that BTS exhibits superior characteristics in terms of cellular uptake, demonstrating a 2-fold to 4-fold greater uptake in vitro compared to BPA. Furthermore, boron retention is significantly higher within cancer cells which retain nearly 60% of the ingested boron after 18 hours, whereas less than 20% is retained after 18 hours with BPA. Notably these results also translated to higher boron delivery over longer periods of time in in vivo experiments. Lastly, the tumor-to-blood ratio with BTS was found to be markedly improved, as high as 28 to 1 compared to only 6 to 1 for BPA, showcasing significantly improved performance in targeting tumors while minimizing exposure to healthy tissue. All these key attributes may be instrumental in enhancing the efficacy of BNCT while minimizing damage to healthy tissues. "TAE Life Sciences' commitment to scientific rigor and innovation is evident in this study," said Dr. Kendall Morrison, Chief Scientific Officer at the company. "The publication of our findings in the Journal of Medicinal Chemistry underscores the meticulous research and robust scientific foundation behind BTS's development and testing." This breakthrough study cements TAE Life Sciences' position as a frontrunner in pioneering cancer treatment advancements in the field of radiation oncology. The promising results pave the way for further research and clinical applications, reaffirming the company's dedication to transforming cancer care. For more information, please refer to the study titled "Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Reemerging Boron Neutron Capture Therapy Field," published in the Journal of Medicinal Chemistry, volume 66, issue 19, pages 13,347 – 13,858. For more information about TAE Life Sciences, Alphabeam, and the company's proprietary boronated BNCT drugs, please visit . About TAE Life Sciences TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences' Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at . Press Contact: Michael Farino New Era Communications 949-346-1984 TAE@newerapr.com SOURCE TAE Life Sciences

Photo Credit: Mito Material Solutions Specialty chemical company, Mito Material Solutions (Indianapolis, Ind., U.S.) announces its first ready-to-pour graphene product with the company’s verified functionalized graphene status, awarded by the Graphene Council (New Bern, N.C., U.S.). In partnership with industrial coatings manufacturer Forrest Technical Coatings (Eugene, Ore., U.S.), Mito has harnessed its patented, verified technology platform for the production of functionalized graphene into ready-to-pour hybrid additives with chemical and physical bonding points. The first two available ready-to-pour products are Mito E-Go Res-1, a laminating epoxy resin, and Mito Tri-Hdnr-1, an epoxy hardener. The ready-made products may be used separately but their formulas are optimized to work together. “The Mito Res-1 and Tri-Hdnr offering is another example of Mito’s commitment to lower barriers to entry for manufacturers who want to see what functionalized graphene can do in their products,” Haley Marie Keith, CEO and co-founder of Mito, says. “I am excited to see what this partnership with Forrest will enable other manufacturers to create. The possibilities with graphene are limitless, but this new product line gives the power of engineering back to the manufacturers to build anything from stronger and lighter boats to snowboards to bikes and more.” Current Mito client, Folsom Skis, first suggested Mito partner with sports industry formulator Forrest Technical Coatings to make E-Go available in the resin to simplify adoption from a production perspective. Armed with that suggestion and the introduction to Forrest, Mito and Forrest teamed up in creating a ready-to-pour resin mix based off Forrest’s most popular SKUs for sports industry companies using compression molding manufacturing techniques for products. E-Go is pre-mixed in an approximate 1-to-1000 ratio to Forrest’s polymer with the goal of simplifying the complexity of process adoption. According to Mito, its products give fiber-reinforced composites and thermoplastics lab-verified improvements in strength, durability, flexibility, functionality and sustainability. As E-Go is a verified functionalized graphene additive, customers have the assurance that E-Go has passed rigorous audits and third-party testing to ensure product consistency and quality at commercial scale.